A Phase 2, Randomized, Open-label Study of Onvansertib in Combination with FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Patients with a KRAS or NRAS Mutation

About

Brief Summary

This study has not yet been registered on ClinicalTrials.gov, which is currently a pre-requisite for display of detailed eligibility criteria.

Phase
Phase II

Join this Trial

Contact our clinical trial navigators for opportunities that may be suitable for you
Study Stats
Protocol No.
PRE22-009612
Category
Hematology-Oncology
Oncology
Principal Investigator
Randolph Hecht
Contact
Aricka Fayton
Location
  • TRIO-US - Los Alamitos CA
  • TRIO-US - Redondo Beach